NeuroMab™ Anti-PSK9 Antibody(NRP-0422-P1556)

Product Overview

Description

The antibody has a pH-dependent antigen-binding antigen, and therefore have greater affinity for antigen binding at physiological pH than at endosomal pH. This can increase the antibody half-life compared to an antibody with an equivalent KD at pH 7.4 but no pH-dependent binding. Antibodies with pH-dependent binding can also prolong the reduction of antigens that are not bound to the antibody. This may be important when antagonizing target antigens that are usually present at high levels.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

Antagonist; In Vitro

Relevant Diseases

Alzheimer's Disease; Stroke; Neuroinflammation

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

> 95% (SDS-PAGE)

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

PSK9

Official Name

PCSK9

Full Name

Proprotein Convertase Subtilisin/Kexin Type 9

Alternative Names

Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia; Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1;

Gene ID

100102(Human)

Uniprot ID

Q80W65(Human)

Product Pictures

FuncS

Figure 1 demonstrates the predictability of pH-dependent antibody modeling. The model successfully predicted the total antibody concentration for 5A10.

FuncS

Figure 2 shows the time course of the total cholesterol effect upon administration of various PCSK9 antibodies.

The figure shows the dose dependent effect of 5A10 on total cholesterol.

FuncS

Figure 3 is a graph showing that antibodies 5L1721H23-6H3 and 5L1721H23-6L3H3 with pH-dependent binding have reduced antibody degradation and increased half-life compared to antibodies without pH-dependent binding.

FuncS

Figure 4 shows the dose-dependent effect of pH-dependent antibody 5L1721H23-6H3. The effect is extended compared to the effect of the 5A10.

FuncS

Figure 5 is a graph showing the time-course effect of 6L3H3 on LDL. The pH-dependent binding antibody 6L3H3 prolongs the interval of LDL reduction compared to 5A10.